Keywords : healthcare reform, healthcare system, healthcare expenditure, disease management, Health Insurance, healthcare coverage, Medicare
About This Report Healthcare expenditure is growing fast in all industries, driven by aging populations, a growing prevalence of chronic diseases, grow ing government healthcare coverage, use of expensive drugs. Also, as a result of the economic downturn, healthcare funding is under increased scrutiny by governments in developed industry s looking to pay down their debts. What's Included in This Report? * ...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
- Publication date: March 2011
- Report price: $ 3 800
About This Report
Healthcare expenditure is growing fast in all industries, driven by aging populations, a growing prevalence of chronic diseases, grow ing government healthcare coverage, use of expensive drugs. Also, as a result of the economic downturn, healthcare funding is under increased scrutiny by governments in developed industry s looking to pay down their debts.
What's Included in This Report?
* An overview of healthcare expenditure in the 12 major industry s
* Insight into the major reforms of healthcare systems in the developed and developing industry s
* An assessment of the regulatory issues that are affecting global pharma industries.
* Analysis of the key pricing and reimbursement controls that are affecting pharma
Key Market Facts
As a result, healthcare reforms in EU and Japan focus on containing costs, without impacting quality of service. Ongoing measures include pricing and reimbursement cuts, bolstering generic usage, as well as other cost cutting tools, with the outcome largely negative for branded pharma.
Although the US health reform law may well result in extended health insurance coverage and increase government involvement in healthcare, costs are expected to escalate. In the short-term though, discounts and rebates implemented as part of the reform are expected to result in drop in US sales.
Reforms in the emerging industry s concentrate on improving the quality and coverage of healthcare, providing opportunities for pharma, particularly for generic drugs manufacturers. Nevertheless, as healthcare access grow s and quality improves, funding pressures increase, leading to the About This Report of cost-containment.
Why Should You Buy This Report?
* Evaluate key factors driving healthcare expenditure as well as measures implemented by governments strategies implemented to contain further growth.
* Get detailed data into the impact of healthcare reforms in the developed and emerging industry s and their impact on pharma.
* Assess pharma’s responses to the increasingly tough regulatory and reimbursement environment.
Managed Care Industry in Spain
Summary
Introduction
Strategic scoping and focus
Main Facts
Key growth drivers and resistors facing healthcare payers and pharma
Healthcare spending
Healthcare reforms
Regulatory issues
Pricing and reimbursement
Related Reports
Upcoming related reports
HEALTHCARE EXPENDITURE
Healthcare spending is growing fast
There are several factors driving up healthcare spending across the industry s analyzed:
The proportion of public contribution to healthcare is greater in the developed as compared to the emerging industry s
However, despite improving economies, the emerging industry s like the developed industries, are under pressure to contain costs, leading to implementation of strategies such as price cuts that are impacting pharma industry players operating in such industries.
Pharmaceutical spending is increasing in all industry s
HEALTHCARE REFORMS
Healthcare reforms focus on improving access and cutting costs
The main aim of healthcare reforms in the EU and Japan is to contain costs
France is reforming hospital management to reduce costs
Germany is transferring cost of healthcare onto individuals to rein in spending
Italy has been engaged in a raft of healthcare reforms
Spain’s recent healthcare reforms have focused on pricing and reimbursement issues
UK primary care trusts will be phased out
An aging population has necessitated cost-containment measures in Japan
Healthcare reforms in emerging industry s will positively impact pharma
Key aims of healthcare reforms in emerging industry s include the following:
India plans to grow healthcare services
Healthcare continues to be a priority for Brazil’s government
Russia rolls out its 2020 healthcare plan
China is making strides in improving health insurance coverage
Healthcare reforms in the US will largely have a neutral impact on pharma
Healthcare reform has already had an impact on pharma in 2010
Will the healthcare reform law be repealed?
Potential impact of healthcare reform on pharmaceutical sales
Healthcare systems globally are converging towards a similar model
Closes payer-pharma relationships set to evolve
Disease management will become central to payer decisions
Pharma will need to manage both patient and payer expectations
Several key industry s are decentralizing healthcare decision-making to increase efficiency
UK’s decentralization strategy has raised concerns regarding inequality of access to healthcare services
Italy has already devolved many powers to regions causing inequality in access to care and treatments
Brazil, Russia, and China are also engaging in decentralization strategies
REGULATORY ISSUES
Regulatory changes have a largely negative impact on pharma
Heightened safety concerns continue to impact pharma
Collaboration between the FDA and EMA is intensifying
EU ban on direct-to-patient communication guidelines partially relaxed
Developed industry s exhibit a stable intellectual property environment
It is generally easier to secure patent protection in the US than in the EU
The EU follows the 8+2+1 rule
Japan gives branded pharma industry players 8 years of data exclusivity through re-evaluation requirement
Springboarding allows generics drugs manufacturers to access branded drug data in Australia
Loss of Plavix exclusivity in Germany is thought to be an exception
The EU’s move to a single patent has been held up
The intellectual property environments in the emerging industry s are seen as inadequate
Russia’s intellectual properly environment is characterized by corruption
Patent reviews are slow in Brazil
Indian law does not contain statutory data protection
China is not yet affording adequate data protection for new chemical entities
PRICING AND REIMBURSEMENT
Key global pricing and reimbursement controls
Pricing controls
Reimbursement controls
Pricing and reimbursement cuts were key elements included in austerity measures in many developed industry s
Patent-protected drugs are spared by Italian price cuts but off-patent and generic drugs suffer
Austerity measures in France impact both prices and reimbursement rates
Spain’s price cuts impact both branded and generic medicines
Germany’s new law focuses on containing the growth of spending on patent-protected drugs
Australia’s changing reimbursement landscape puts pressure on local generics drugs segment
Japan continues to focus on drug price cutting as its main cost-containment measure
US pharma industry players are impacted by higher rebates and discounts, but escape Medicare drug price negotiation
Pharma shows a strong reaction to price cuts in certain industry s
Pricing pressures are also felt in the emerging industry s
Brazil is widening free access of drugs to patients
China introduces tighter pricing controls on foreign pharmaceuticals
Russia has increased its drug price controls
India threatens to grow drug pricing controls
Branded pharma adopts flexible pricing strategies to capture emerging industry s growth
Raised cost-effectiveness barriers lead to reimbursement restrictions
The UK is a difficult industry to access for expensive therapies
It is becoming increasingly difficult to obtain a high price for new drugs in France
Achieving premium drug pricing in Japan is difficult
Germany is using cost-effectiveness in its drug evaluations
Comparative effectiveness analysis is starting to be used even in the US
Risk-sharing is becoming a viable option for both payers and market, particularly in EUR pe
UK is one of the leaders in risk-sharing agreements
Italy has a number of performance-based risk-sharing schemes for oncology drugs
Risk-sharing schemes are also appearing in the US but in a fragmented manner
Australia’s risk-sharing agreements lack transparency
Risk-sharing agreements with individual sickness funds are used to boost industry share in Germany
Price negotiation may be the way of the future
Value-based pricing in the UK to be introduced in 2014
Germany introduces drug price negotiation
BIBLIOGRAPHY
Publications and online articles
Datamonitor reports
APPENDIX
Exchange rates used in this report
Health Insurance in Spain
- $ 250
- Industry data
- January 2013
Yearly, From 1996 To 2008
By Business Monitor International
Source: World Health Organization (WHO), BMI
- Industries : Managed Care
- Countries : Spain
- $ 250
- Industry data
- January 2013
Yearly, From 1996 To 2008
By Business Monitor International
Source: World Health Organization (WHO), BMI
- Industries : Managed Care
- Countries : Spain
- $ 250
- Industry data
- January 2013
Yearly, From 1996 To 2008
By Business Monitor International
Source: World Health Organization (WHO), BMI
- Industries : Managed Care
- Countries : Spain
- $ 250
- Industry data
- January 2013
Yearly, From 1996 To 2008
By Business Monitor International
Source: World Health Organization (WHO), BMI
- Industries : Managed Care
- Countries : Spain
Managed Care in Spain
- $ 250
- Industry data
- January 2013
Yearly, From 2004 To 2021
By Business Monitor International
Source: Association of the European Self-Medication Industry (AESGP), IMS Health, Spanish Association for Se
- Industries : Managed Care
- Countries : Spain
- $ 250
- Industry data
- January 2013
Yearly, From 1996 To 2008
By Business Monitor International
Source: World Health Organization (WHO), BMI
- Industries : Managed Care
- Countries : Spain
- $ 250
- Industry data
- January 2013
Yearly, From 1996 To 2021
By Business Monitor International
Source: World Health Organization (WHO), BMI
- Industries : Managed Care
- Countries : Spain
- $ 250
- Industry data
- January 2013
Yearly, From 1997 To 2021
By Business Monitor International
Source: World Health Organization (WHO), BMI
- Industries : Managed Care
- Countries : Spain
- $ 250
- Industry data
- January 2013
Yearly, From 1997 To 2021
By Business Monitor International
Source: World Health Organization (WHO), BMI
- Industries : Managed Care
- Countries : Spain
- Publication date: March 2011
- Report price: $ 3 800
